Biology Reference
In-Depth Information
a trial of R-HuEPO due to thrombotic events.
J Pain Symptom Manage 27:185-190
37. Stohlawetz PJ, Dzirlo L, Hergovich N et al
(2000) Effects of erythropoietin on platelet
reactivity and thrombopoiesis in humans.
Blood 95:2983-2989
38. Kirkeby A, Torup L, Bochsen L et al (2008)
High-dose erythropoietin alters platelet reactivity
and bleeding time in rodents in contrast to the
neuroprotective variant carbamyl-erythropoietin
(CEPO). Thromb Haemost 99:720-728
39. Belonje AM, Voors AA, van Gilst WH, van
Veldhuisen DJ (2007) Erythropoietin in
chronic heart failure. Congest Heart Fail
13:289-292
40. Ehrenreich H, Weissenborn K, Prange H et al
(2009) Recombinant human erythropoietin in
the treatment of acute ischemic stroke. Stroke
40:e647-e656
41. Brines M, Cerami A (2008) Erythropoietin-
mediated tissue protection: reducing collateral
damage from the primary injury response.
J Intern Med 264:405-432
42. Campana WM, Misasi R, O'Brien JS (1998)
Identification of a neurotrophic sequence in
erythropoietin. Int J Mol Med 1:235-241
43. Leist M, Ghezzi P, Grasso G et al (2004)
Derivatives of erythropoietin that are tissue
protective but not erythropoietic. Science
305:239-242
44. Brines M, Patel NS, Villa P et al (2008)
Nonerythropoietic, tissue-protective peptides
derived from the tertiary structure of erythropoie-
tin. Proc Natl Acad Sci U S A 105:10925-10930
45. Brines M, Cerami A, Coleman T (2009) Tissue
protective peptides and uses thereof. US Patent
Application
46. Colella P, Iodice C, Di Vicino U et al (2011)
Non-erythropoietic erythropoietin derivatives
protect from light-induced and genetic photo-
receptor degeneration. Human Mol Genet
20(11):2251-2262
47. Sullivan T, Kodali K, Rex TS (2011) Systemic
gene delivery protects the photoreceptors in
the retinal degeneration slow mouse.
Neurochem Res 36:613-618
48. Auricchio A, Kobinger G, Anand V et al (2001)
Exchange of surface proteins impacts on viral
vector cellular specificity and transduction
characteristics: the retina as a model. Hum
Mol Genet 10:3075-3081
49. Merten OW, Al-Rubeai M (2011) Viral vec-
tors for gene therapy. Methods and protocols,
vol 737, 1st edn. Humana, New York
50. Organisciak DT, Vaughan DK (2010) Retinal
light damage: mechanisms and protection.
Prog Retin Eye Res 29:113-134
51. Xiao W, Chirmule N, Berta SC et al (1999)
Gene therapy vectors based on adeno-associ-
ated virus type 1. J Virol 73:3994-4003
52. LaVail MM, Unoki K, Yasumura D et al (1992)
Multiple growth factors, cytokines, and neu-
rotrophins rescue photoreceptors from the
damaging effects of constant light. Proc Natl
Acad Sci U S A 89:11249-11253
53. Weymouth AE, Vingrys AJ (2008) Rodent
electroretinography: methods for extraction
and interpretation of rod and cone responses.
Prog Retin Eye Res 27:1-44
54. Auricchio A (2003) Pseudotyped AAV vectors
for constitutive and regulated gene expression
in the eye. Vision Res 43: 913-918
55. Vandenberghe LH, Wilson JM, Gao G (2009)
Tailoring the AAV vector capsid for gene
therapy. Gene Ther 16:311-319
2009/0221482,
Warren
Pharmaceuticals, Inc.
Search WWH ::
Custom Search